UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 182

Sortiert nach

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3327-3334

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1227-1234

2009

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

The lancet oncology, 2015-02, Vol.16 (2), p.141-151

2015

Link zum Volltext

Verfügbarkeit prüfen

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2055-2062

2012

Link zum Volltext

Verfügbarkeit prüfen

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1676-1688

2016

Link zum Volltext

Verfügbarkeit prüfen

Impact of EGFR Inhibitor in Non―Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

JNCI : Journal of the National Cancer Institute, 2013-05, Vol.105 (9), p.595-605

2013

Link zum Volltext

Verfügbarkeit prüfen

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3342-3350

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Journal of clinical oncology, 2011-03, Vol.29 (9), p.1125-1132

2011

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Journal of clinical oncology, 2012-04, Vol.30 (10), p.1114-1121

2012

Link zum Volltext

Verfügbarkeit prüfen

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

Journal of clinical oncology, 2010-02, Vol.28 (5), p.744-752

2010

Link zum Volltext

Verfügbarkeit prüfen

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

The Lancet (British edition), 2008-11, Vol.372 (9652), p.1809-1818

2008

Link zum Volltext

Verfügbarkeit prüfen

Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?

Anti-cancer agents in medicinal chemistry, 2012-02, Vol.12 (2), p.137

Hirsh, Vera

2012

Link zum Volltext

Verfügbarkeit prüfen

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2020-01, Vol.25 (1), p.64-77

2020

Link zum Volltext

Verfügbarkeit prüfen

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

British journal of cancer, 2017-01, Vol.116 (2), p.175-185

2017

Link zum Volltext

Verfügbarkeit prüfen

Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer

Canadian Association of Radiologists journal, 2021-02, Vol.72 (1), p.109-119

2021

Link zum Volltext

Verfügbarkeit prüfen

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2015-06, Vol.29 (3), p.167-183

Hirsh, Vera

2015

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic acid use in cancer patients

Cancer, 2011-01, Vol.117 (1), p.11-23

2011

Link zum Volltext

Verfügbarkeit prüfen

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Frontiers in oncology, 2017-05, Vol.7, p.97-97

2017

Link zum Volltext

Verfügbarkeit prüfen

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Therapeutic Advances in Medical Oncology, 2018-01, Vol.10, p.1758834017753338-1758834017753338

Hirsh, Vera

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2667-2674

2011

Link zum Volltext

Verfügbarkeit prüfen

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

Lung cancer (Amsterdam, Netherlands), 2019-07, Vol.133, p.10-19

2019

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2008-08, Vol.26 (24), p.3979-3986

2008

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3150-3157

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 182

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(177)

Publikationsform

Sprache

Englisch
(178)
Japanisch
(17)
Russisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(96)
Oncology
(84)
Humans
(77)
Lung Neoplasms - Drug Therapy
(58)
Female
(56)
Male
(55)
Middle Aged
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(49)
Aged
(46)
Adult
(43)
Lung Neoplasms - Pathology
(37)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(35)
Aged, 80 And Over
(30)
Biological And Medical Sciences
(28)
Lung Cancer
(28)
Treatment Outcome
(28)
Medical Sciences
(27)
Lung Neoplasms - Mortality
(26)
Chemotherapy
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition

Impact of EGFR Inhibitor in Non―Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First‐Line Non‐Small Cell Lung Cancer

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

Radiogenomic Models Using Machine Learning Techniques to Predict EGFR Mutations in Non-Small Cell Lung Cancer

Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib

Zoledronic acid use in cancer patients

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

Suchergebnisse filtern